In conclusion, no long-term safety problems were observed in a limited number of miravirsen-treated patients and targeting of miR-122 may be an effective treatment strategy for HCV infected patients. This study was initiated by the Academical Medical Center, Amsterdam in the Netherlands. Other participating hospitals were Erasmus Medical Center in the Netherlands, J.W. Goethe University Hospital in Germany, University of Texas Health Science Centre in the USA, Fundacion de Investigacion in Porto Rico, University Hospital Bratislava in Slovakia and Medical University of Warsaw in Poland in collaboration

with PRA International and Santaris Pharma. “
“This article provides an overview of the invited lectures at the 27th International Conference on Antiviral Research, sponsored Galunisertib by the International Society for Antiviral Research (ISAR), which was held in Raleigh, North Carolina, USA from May 12 to 16, 2014. It begins with reports of lectures by the recipients of ISAR’s three major awards, held in memory of Gertrude Elion, Antonín Holý and William Prusoff. These are

followed by brief summaries of the keynote addresses and the three mini-symposia on “Hepatitis B virus”, “Research Triangle Park” and “Challenges GDC-0199 datasheet in HIV infection, treatment and prevention”. Because this review article simply provides short accounts of oral presentations, it is not generally accompanied by references to the scientific literature. Any descriptions of favorable treatment outcomes should not be taken as recommendations for clinical use. John C. Drach, Ph.D., University of Michigan, Ann Arbor, Michigan, USA (Fig. 1). Gertrude B. (Trudy) Elion was born in New York City and was pleased to work for the Burroughs Wellcome Co. when based in New York but was concerned when it transferred to Research Triangle Park, North Carolina,

not many miles from this year’s meeting site. However, within just a few months she declared that she was “at home” in North Carolina. She was awarded the Nobel Prize in Physiology or Medicine in 1988 for her pioneering work in purine biosynthesis which paved the way for the discovery of drugs to treat organ rejection, cancer and viral diseases. The focus of PAK5 John’s presentation was on the research conducted in his own and his collaborators’ laboratories that ultimately led to the invention of three compounds which were discovered to have antiviral activity against human cytomegalovirus (HCMV) and which later entered clinical trials: BDCRB pyranoside (GW275175X) (Phase I), maribavir (Phases I, II and III) and cyclopropavir (Phase I). His major collaborators included Karen Biron, Charles Shipman, Leroy Townsend, and Jiri Zemlicka. To date, there are only five FDA-approved drugs for treatment of HCMV infections: cidofovir, fomivirsen, foscarnet, ganciclovir and valganciclovir.